Acumen Pharmaceuticals and NKGen Biotech are set to present their latest research on Alzheimer's disease at the 17th Annual Clinical Trials on Alzheimer's Disease (CTAD) conference in Madrid, Spain, from October 29 to November 1, 2024. These presentations highlight novel approaches in screening and immunotherapy for Alzheimer's.
Acumen's Screening Approach with pTau217 Assay
Acumen Pharmaceuticals (NASDAQ: ABOS) will deliver a late-breaking presentation on the participant screening approach used in their ongoing Phase 2 ALTITUDE-AD clinical trial. The trial is evaluating sabirnetug (ACU193), a humanized monoclonal antibody, for the treatment of early Alzheimer's disease. Sabirnetug selectively targets soluble amyloid beta oligomers (AβOs), which are considered a highly toxic form of Aβ.
The presentation will focus on the use of a validated research-use plasma pTau217 assay to screen potential participants for the ALTITUDE-AD trial. Phosphorylated tau at position 217 (pTau217) is a biomarker indicative of Alzheimer's disease pathology. The plasma pTau217 assay serves as an initial screening tool to identify individuals who may qualify for further amyloid testing to determine their eligibility for the trial.
Todd Feaster, Psy.D., Senior Clinical Research Scientist at Acumen Pharmaceuticals, will present the data on Thursday, October 31, 2024, at 9:30 a.m. CET. The presentation, titled "ALTITUDE-AD: Use of a Validated p-tau217 Assay to Screen Potential Participants in an Ongoing Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Sabirnetug for Participants with Early Alzheimer's Disease," will take place in the Auditorium of the Madrid Marriott Auditorium Hotel and Conference Center.
NKGen Biotech's Natural Killer Cell Therapy
NKGen Biotech Inc. (Nasdaq: NKGN) will present posters on their research involving troculeucel, an autologous natural killer (NK) cell therapy, for Alzheimer's disease. The presentations will include a final report of a Phase 1 dose escalation study and a preliminary report of the Phase 1 cohort in the follow-up Phase 1/2a study.
Two posters will be presented:
- LP020: "Treatment of Moderate Alzheimer’s Disease Subjects with Expanded Non-genetically Modified Natural Killer Cells (troculeucel; SNK01) with Enhanced Activity – Report of the Phase I results of the Phase I/IIa Study"
- P105: "Use of Non-genetically Modified Natural Killer Cells (SNK01) With Enhanced Activity in Subjects with Active Alzheimer’s Disease. Further Biomarker Analysis and Implications for Use in Prevention"
Both poster sessions will be held from Tuesday, October 29, 2024, 3:00 pm to Wednesday, October 30, 2024 – 5:00 pm CET.
Troculeucel is a patient-specific, ex vivo expanded autologous NK cell immunotherapeutic drug candidate. NKGen is developing troculeucel for neurodegenerative disorders and various cancers. The World Health Organization (WHO) has assigned troculeucel as the International Nonproprietary Name (INN) for SNK01.
About the Clinical Trials
Acumen's ALTITUDE-AD is a Phase 2, multi-center, randomized, double-blind, placebo-controlled clinical trial. It aims to evaluate the efficacy and safety of sabirnetug (ACU193) infusions, administered once every four weeks, in slowing cognitive and functional decline compared to placebo in participants with early Alzheimer's disease. The study plans to enroll approximately 540 individuals with early Alzheimer’s disease (mild cognitive impairment or mild dementia due to AD) across sites in the United States, Canada, UK, and the European Union (NCT06335173).
NKGen's studies explore the potential of troculeucel in treating Alzheimer's disease through the modulation of the immune system using natural killer cells.
